Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[225Ac]Ac-FL-261 in Solid Tumors Overexpressing c-MET
NCT07873450Phase 2Recruiting
- Sponsor
- Full-Life Technologies
- Start
- Oct 2026
- Primary completion
- Jun 2030
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of [225Ac]Ac-FL-261 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 2 more (3 arms), sponsored by Full-Life Technologies. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events at 5 years and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
[225Ac]Ac-FL-261
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07873450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07873450.